About: Antiviral treatment for outpatient use during an influenza pandemic: a decision tree model of outcomes averted and cost-effectiveness

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Antiviral treatment for outpatient use during an influenza pandemic: a decision tree model of outcomes averted and cost-effectiveness Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Antiviral treatment for outpatient use during an influenza pandemic: a decision tree model of outcomes averted and cost-effectiveness
Creator	Nguyen-Van-Tam, Jonathan Biggerstaff, Matthew Myles, Puja Carias, Cristina Campbell, Angela Meltzer, Martin Kahn, Emily Venkatesan, Sudhir
Source	PMC
abstract	BACKGROUND: Many countries have acquired antiviral stockpiles for pandemic influenza mitigation and a significant part of the stockpile may be focussed towards community-based treatment. METHODS: We developed a spreadsheet-based, decision tree model to assess outcomes averted and cost-effectiveness of antiviral treatment for outpatient use from the perspective of the healthcare payer in the UK. We defined five pandemic scenarios—one based on the 2009 A(H1N1) pandemic and four hypothetical scenarios varying in measures of transmissibility and severity. RESULTS: Community-based antiviral treatment was estimated to avert 14–23% of hospitalizations in an overall population of 62.28 million. Higher proportions of averted outcomes were seen in patients with high-risk conditions, when compared to non-high-risk patients. We found that antiviral treatment was cost-saving across pandemic scenarios for high-risk population groups, and cost-saving for the overall population in higher severity influenza pandemics. Antiviral effectiveness had the greatest influence on both the number of hospitalizations averted and on cost-effectiveness. CONCLUSIONS: This analysis shows that across pandemic scenarios, antiviral treatment can be cost-saving for population groups at high risk of influenza-related complications.
has issue date	2018-06-28(xsd:dateTime)
bibo:doi	10.1093/pubmed/fdy108
bibo:pmid	29955851
has license	no-cc
sha1sum (hex)	dfcc1ab3b54323245310090273b251e7e7b924a5
schema:url	https://doi.org/10.1093/pubmed/fdy108
resource representing a document's title	Antiviral treatment for outpatient use during an influenza pandemic: a decision tree model of outcomes averted and cost-effectiveness
has PubMed Central identifier	PMC7313872
has PubMed identifier	29955851
schema:publication	J Public Health (Oxf)
resource representing a document's body	covid:dfcc1ab3b54323245310090273b251e7e7b924a5#body_text
is schema:about of	named entity 'acquired' named entity 'Antiviral' named entity 'COUNTRIES' named entity 'Background' named entity 'influenza' named entity 'stockpiles' named entity 'Antiviral treatment' named entity 'high-risk' named entity 'sensitivity analysis' named entity 'meta-analysis' named entity 'World Health Organization' named entity 'high-risk' named entity 'influenza' named entity 'influenza' named entity 'pandemics' named entity 'sensitivity analysis' named entity 'hospital capacity' named entity 'British Pound Sterling' named entity 'CDC' named entity 'IPD' named entity 'high-risk' named entity 'clinical trial' named entity 'oseltamivir' named entity 'confidence intervals' named entity 'antiviral' named entity 'antiviral drug' named entity 'symptom' named entity 'seasonal influenza' named entity 'influenza' named entity 'British National Formulary' named entity 'pandemics' named entity 'high-risk' named entity 'relative risk' named entity 'symptom' named entity 'United States' named entity 'prophylaxis' named entity 'high-risk' named entity 'pandemics' named entity 'public health emergencies' named entity 'influenza' named entity 'symptom' named entity 'spreadsheet' named entity 'pandemic influenza' named entity 'UK National Health Service' named entity 'symptom' named entity 'probability' named entity 'high-risk' named entity 'outpatient' named entity 'influenza' named entity 'H1N1' named entity 'outpatient' named entity 'high-risk' named entity 'ILI' named entity 'NPFS' named entity 'influenza' named entity 'decision tree model' named entity 'oseltamivir' named entity 'symptom' named entity 'sensitivity analysis' named entity 'hospital capacity' named entity 'hospital capacity' named entity 'Appendix 1' named entity 'oseltamivir' named entity 'sensitivity analysis' named entity 'high-risk' named entity 'ILI' named entity 'fourth pandemic' named entity 'Journal of Public Health' named entity 'Monte Carlo simulation' named entity 'high-risk' named entity 'antiviral therapies' named entity 'decision tree model' named entity 'influenza transmission' named entity 'high-risk'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software